MENU

Can Waters Corporation (WAT) Stock Reach $515?

a manufacturer of analytical technologies: liquid chromatography, mass spectrometry, and thermal analysis

A.I.Advisor
published price charts
A.I.Advisor
Nov 02, 2026

Can Waters Corporation (WAT) Stock Reach $515?

Waters Corporation (WAT), the analytical-instruments maker behind liquid chromatography, mass spectrometry, and thermal-analysis systems, has been one of the most dramatically re-rated names in the life-sciences-tools sector since it closed its combination with Becton Dickinson's Biosciences and Diagnostic Solutions business in February 2026. With shares trading near a record high, investors are asking whether the stock can push toward $515.

Key Takeaways

  • The $515 target is a publicly discussed objective, not an official consensus: it matches the highest tier of current analyst price targets, published by both TD Cowen and Goldman Sachs, and sits just above the stock's record high.
  • With shares near $462.72, reaching $515 would require roughly an 11% move, a modest climb by recent standards.
  • The broader analyst picture is essentially flat to the current price: across roughly 23 analysts, the mean target is near $466, with a wide range of about $349 to $530.
  • Strongest supports include the completed BDS combination, a four-division reorganization, and fiscal-2026 revenue guidance near $6.4 billion.
  • Biggest risks include integration costs, elevated leverage, negative GAAP (generally accepted accounting principles) earnings and free cash flow since closing, and competition from larger peers.
  • Readers can track Major News, Today's Price Move, Forecast, and Earnings on additional pages for deeper context.
  • Explore Trending AI Robots to see how AI-driven trading strategies are navigating the current market.

Analyst Price Targets and Consensus View

The $515 figure used here is not an aggregate consensus. Because Waters' stock has rallied sharply, the average analyst price target has essentially converged with the market price, leaving no meaningful upside buffer. S&P Global data shows about 23 analysts covering the stock with a mean target near $466 and a wide range from roughly $349 to $530. Since that mean sits only marginally above the current price, it does not provide a usable 10%-plus upside objective.

Instead, the $515 level is the top tier of named, current analyst objectives. TD Cowen raised its target to $515 from $475 in October 2026, and Goldman Sachs lifted its target to $515 from $465 in September. Other recent moves reflect a broadly positive, if contested, view: Barclays went to $500, Guggenheim to $490, UBS upgraded the stock to Buy with a $490 target, Piper Sandler upgraded to Overweight with $480, and Citi set $470. Meanwhile, Bank of America, J.P. Morgan, Morgan Stanley, and Bernstein hold targets of $465, $435, $430, and $450, respectively, reflecting the cautious side of the Street.

Current Market Position and Path Toward the Target

Waters closed near $462.72 in late October 2026, just below an intraday record around $482. Reaching $515 implies roughly 11% additional upside, a modest move relative to the stock's roughly 35% gain over the prior 52 weeks. The path depends on whether the combined company can translate the BDS deal into sustained revenue and margin expansion. Consensus adjusted EPS (earnings per share) for fiscal 2026 is near $14.58, and the forward P/E (price-to-earnings ratio) sits in the high-20s to low-30s range, leaving room for multiple expansion only if execution stays on track.

What Could Support a Move Toward the Target

  • The BDS combination materially expanded Waters' scale and moved it into diagnostics and high-volume regulated testing, with fiscal-2026 revenue guided to roughly $6.42 billion to $6.48 billion.
  • A four-division reorganization aims to focus the portfolio on high-growth, higher-margin applications in therapeutics, food, environmental testing, and specialty diagnostics.
  • Analyst revisions turned clearly upward through October 2026, including several target increases and upgrades tied to synergy expectations and an instrument replacement cycle.
  • The company has continued to launch new products, including mass-spectrometry platforms and a charged-aerosol detector, supporting its competitive position.

What Could Prevent the Target From Being Reached

  • Integration risk is real: GAAP net income has been negative in the post-closing quarters, and trailing free cash flow has been slightly negative, even as adjusted figures look healthier.
  • The deal added roughly $4 billion of debt against about $539 million of cash, limiting flexibility until leverage comes down.
  • Competition from Thermo Fisher (TMO), Agilent (A), and Danaher's (DHR) SCIEX remains intense on price and bundled services.
  • Waters remains exposed to cyclical pharma capital spending, academic and government research funding, and China stimulus and tariff dynamics.
  • After an extended rally, valuation compression is a risk if synergy targets or the instrument cycle disappoint.

Technical Levels and Market Structure

The stock has spent the year climbing from a 52-week low near $282.77 to a record high around $482.28. The 50-day moving average sits near $424 to $430, and the 200-day average is closer to $367, indicating a firmly established uptrend but also a sizable gap above longer-term support. The psychologically important $500 level is the first milestone ahead of $515, with the recent all-time high around $482 serving as near-term resistance-turned-support if the breakout holds.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may differ. Key upcoming items include the November 3, 2026 earnings report, fiscal-2026 guidance and any 2027 outlook, progress on BDS synergies and deleveraging, and further analyst target revisions. Investors should also watch macroeconomic inputs such as interest-rate policy, pharma capital-expenditure trends, and China demand, all of which can move instrument orders and the stock's multiple.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single indicator, the system distills large volumes of data into actionable, easy-to-scan signals. Traders can use these tools to discover new opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening alone. If you are looking for a systematic way to track names like Waters alongside the broader market, consider exploring the AI Daily Buy/Sell Signals dashboard.

Final Assessment

The question of whether Waters can reach $515 hinges less on a consensus forecast than on execution. The $515 level reflects the top tier of current analyst objectives and a technical milestone above the stock's record high, requiring roughly 11% upside from recent prices. Support comes from the completed BDS combination, a restructured portfolio, and upward analyst revisions. The principal obstacles are integration costs, elevated leverage, negative GAAP earnings and free cash flow, and stiff competition. With the average analyst target near $466 sitting essentially flat to the price, and individual targets spanning roughly $349 to $530, Wall Street is genuinely divided. The next earnings report and any synergy or deleveraging milestones will be the most important signposts for whether that next leg toward $515 is realistic.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

WAT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, WAT has been closely correlated with A. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if WAT jumps, then A could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WAT
1D Price
Change %
WAT100%
+3.63%
A - WAT
67%
Closely correlated
+2.97%
RVTY - WAT
60%
Loosely correlated
+3.14%
TMO - WAT
60%
Loosely correlated
+0.87%
BRKR - WAT
58%
Loosely correlated
+3.10%
RGEN - WAT
56%
Loosely correlated
+6.47%
More

Groups containing WAT

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WAT
1D Price
Change %
WAT100%
+3.63%
WAT
(3 stocks)
96%
Closely correlated
-1.66%
Can Waters Corporation (WAT) Stock Reach $515?